How do drugs relieve neurogenic pain?

Drugs and Aging

Volumn 11, Issue 5, 1997, Pages 398-412

  Karlsten, Rolf ^a   Gordh, Torsten ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR STIMULATING AGENT; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTINOCICEPTIVE AGENT; BENZODIAZEPINE DERIVATIVE; CAPSAICIN; CLONIDINE; GABAPENTIN; GUANETHIDINE; LOCAL ANESTHETIC AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OPIATE; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ANTINOCICEPTION; CONTROLLED STUDY; HUMAN; NEUROGENIC PAIN; NONHUMAN; PAIN; PRIORITY JOURNAL; REVIEW;

EID: 0030731134     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199711050-00006     Document Type: Review

References (133)

1. Arnér S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988; 33: 11-23
2. Besson J-M. The pharmacology of pain: twenty-five years of hope, despair, and hope. In: Gebhart GF, Hammond DL, Jensen TS, editors. Proceedings of the 7th World Congress of Pain. Progress in pain research and management. Seattle: International Association for the Study of Pain (IASP) Press, 1994: 23-39
3. Fields HL, Rowbotham MC. Multiple mechanisms of neuropathic pain: a clinical perspective. In: Gebhart GF, Hammond DL, Jensen TS, editors. Proceedings of the 7th World Congress on Pain. Progress in pain research and management. Seattle: IASP Press, 1994: 437-54
4. Bowsher D. Neurogenic pain syndromes and their management. Br Med Bull 1991; 47: 644-66
5. Macrae WA, Davies HTO, Crombie IK. Pain: paradigms and treatment. Pain 1992; 49: 289-91
6. Davies HT, Crombie IK, Macrae WA. Polarised views on treating neurogenic pain. Pain 1993; 54: 341-6
7. Davies HT, Crombie IK, Macrae WA. Why use a pain clinic? Management of neurogenic pain before and after referral. J R Soc Med 1994; 87: 382-5
8. Boivie J. Pain in neurology and neurosurgery: introduction. In: Campbell JN, editor. Pain 1996 - an updated review. Seattle: IASP Press, 1996: 19
9. Mersky H. An investigation of pain in psychological illness [thesis]. Oxford: University of Oxford, 1964
10. International Association for the Study of Pain (IASP) X. Pain terms: list with definitions and notes on usage. Pain 1979; 6: 249
11. Wilson PR, Lamer TJ. Pain mechanisms: anatomy and physiology. In: Raj PP, editor. Practical management of pain. St Louis (MO): Mosby-Year Book, 1992: 65-80
12. Samuelsson H, Malmberg F, Eriksson M, et al. Outcomes of epidural morphine treatment in cancer pain: nine years of clinical experience. J Pain Symptom Manage 1995; 10: 105-12
13. Jensen TS. Mechanisms of neuropathic pain. In: Campbell JN, editor. Pain 1996 - an updated review. Seattle: IASP Press, 1996: 77-86
14. Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of post-herpetic neuralgia. Neurology 1991; 41: 1024-8
15. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 1990; 43: 273-86
16. Cherney NI, Thaler HT, Friedlander-Klar H, et al. Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, single-dose studies. Neurology 1994; 44: 857-61
17. Foley KM. Misconceptions and controversies regarding the use of opioids in cancer pain. Anticancer Drugs 1995; 6: 4-13
18. Eide P, Stubhaug A, Öje I. The NMDA-antagonist ketamine for the treatment and prevention of acute and chronic postoperative pain. In: Breivik H, editor. Clinical anaesthesiology: post-operative pain management. London: Saunders, 1995: 539-55
19. Devor M. The pathophysiology and anatomy of damaged nerves. In: Wall PD, Melzack R, editors. Textbook of pain. New York: Churchill Livingstone, 1994: 79-101
20. Woolf CJ, Shortland P, Coggeshall RE. Peripheral nerve injury triggers central sprouting of the myelinated afferents. Nature 1992; 355: 75-7
21. Devor M, Wall PD, Catalan N. Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction. Pain 1992; 48: 261-8
22. Dickenson AH. Central acute pain mechanisms. Ann Med 1995; 27: 223-7
23. Steel JH, Terenghi G, Chung JM, et al. Increased nitric oxide synthetase immunoreactivity in rat dorsal horn ganglia in a neuropathic pain model. Neurosci Lett 1994; 169: 81-4
24. Hökfelt T, Zhang X, Wiesenfeld-Hallin Z. Messenger plasticity in primary sensory neurons following axotomy and its functional implications. Trends Neurosci 1994; 17: 22-30
25. Hsieh JC, Belfrage M, Stone-Elander S, et al. Central representation of chronic ongoing neuropathic pain studied by positron emission tomography. Pain 1995; 63: 225-36
26. Bennett GJ. Animal models of neuropathic pain. In: Gebhart GF, Hammond DL, Jensen TS, editors. Proceedings of the 7th World Congress on Pain. Progress in pain research and management. Seattle: IASP Press, 1994: 495-510
27. Ochoa JL, Verdugo RJ, Campero M. Pathophysiological spectrum of organic and psychogenic disorders in neurogenic disorders in neuropathic pain patients fitting the description of causalgia or reflex sympathetic dystrophy. In: Gebhart GF, Hammond DL, Jensen TS, editors. Proceedings of the 7th World Congress on Pain. Progress in pain research and management. Seattle: IASP Press, 1994: 483-94
28. Sang CN, Gracely RH, Max MB, et al. Capsaicin-evoked mechanical allodynia and hyperalgesia cross nerve territories. Anesthesiology 1996; 85: 491-6
29. Hansson P. Neurogenic pain: diagnosis and treatment. Pain Clin Updates 1994; II: 1-4
30. Boivie J. Central pain syndromes. In: Campbell JN, editor. Pain 1996 - an updated review. Seattle: IASP Press, 1996: 23-9
31. Boivie J, Leijon G, Johansson L. Central post-stroke pain - a study of the mechanisms through analysis of the sensory abnormalities. Pain 1989; 37: 173-85
32. Vestergaard K, Nielsen J, Andersen G, et al. Sensory abnormalities in consecutive, unselected patients with central post-stroke pain. Pain 1995; 61: 177-86
33. Andersen G, Vestergaard K, Ingeman Nielsen M, et al. Incidence of central post-stroke pain. Pain 1995; 61: 187-93
34. Rowbotham MC. Topical analgesic agents. In: Fields HL, Liebeskind JC, editors. Progress in pain research and management. Seattle: IASP Press, 1994: 211-29
35. Rains C, Bryson HM. Topical capsaicin: a review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis. Drugs Aging 1995; 7 (4): 317-28
36. Buck SH, Burks TF. The neuropharmacology of capsaicin: review of some recent observations. Pharmacol Rev 1986 Sep; 38: 179-226
37. McMahon SB, Lewin G, Bloom SR. The consequences of long-term topical capsaicin application in the rat. Pain 1991; 44: 301-10
38. Watson CPN. The treatment of postherpetic neuralgia. Neurology 1995; 45 Suppl. 8: S58-60
39. Low PA, Opfer-Gehring TL, Dyck PJ, et al. Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy. Pain 1995; 62: 163-8
40. Watson CP. Topical capsaicin as an adjuvant analgesic. J Pain Symptom Manage 1994; 9: 425-33
41. Bonica J. Causalgia and other reflex dystrophies. In: Bonica J, Liebeskind J, Albe-Fessard D, editors. Advances in pain research and therapy. New York: Raven Press, 1979: 141-66
42. Hannington-Kiff JG. Intravenous regional sympathetic block with guanethidine. Lancet 1974; I: 1019-20
43. Torebjörk E, Wahren L-K, Wallin G, et al. Noradrenaline-evoked pain in neuralgia. Pain 1995; 63: 11-20
44. Wahren LK, Gordh T, Torebjörk E. Effects of regional intravenous guanethidine in patients with neuralgia in the hand: a follow-up over a decade. Pain 1995; 62: 379-85
45. Chang CC, Costa E, Brodie BB. Interaction of guanethidine with adrenergic neurons. J Pharmacol Exp Ther 1965; 147: 303-12
46. Casale R, Glynn C, Buonocore M. The role of ischemia in the analgesia which follows Bier's block technique. Pain 1992; 50: 169-75
47. Valentin N. Reflex sympathetic dystrophy treated with guanethidine: time for a change of name and strategy. Acta Anaesthesiol Scand 1996; 40: 1171-2
48. Paoli F, Darcourt G, Corsa P. Note préliminaire sur l'action de l'imipramine dans les états doloreux. Rev Neurol 1960; 2: 503-4
49. Biegon A, Samuel D. Interaction of tricyclic antidepressants with opiate receptors. Biochem Pharmacol 1980; 29: 460-2
50. Isenberg KE, Cicero TJ. Possible involvement of opiate receptors in the pharmacological profiles of antidepressant compounds. Eur J Pharmacol 1984; 103: 57-63
51. Eisenach JC, Gebhart GF. Intrathecal amitriptyline: antinociceptive interactions with IV morphine and intrathecal clonidine, neostigmine and carbamylcholine in rats. Anesthesiology 1995; 83: 1036-45
52. Bromm B, Meier W, Scharein E. Imipramine reduces experimental pain. Pain 1986; 25: 245-57
53. Poulsen L, Arendt Nielsen L, Brosen K, et al. The hypoalgesic effect of imipramine in different human experimental pain models. Pain 1995; 60: 287-93
54. Coquoz D, Porchet HC, Dayer P. Central analgesic effects of antidepressant drugs with various mechanisms of action: desipramine, fluvoxamine and moclobemide. Schweiz Med Wochenschr 1991; 121: 1843-5
55. Eisenach JC. Three novel spinal analgesics: clonidine, neostigmine, amitriptyline. Reg Anesth 1996; 21: 81-3
56. Max MB. Treatment of post-herpetic neuralgia: antidepressants. Ann Neurol 1994; 35 Suppl.: S50-3
57. Bryson HM, Wilde MI. Amitriptyline: a review of its pharmacological properties and therapeutic use in chronic pain states. Drugs Aging 1996; 8 (6): 459-76
58. McQuay HJ, Tramèr M, Nye BA, et al. A systematic review of antidepressants in neuropathic pain. Pain 1996; 68: 217-27
59. Yaksh TL, Aimone LD. The central pharmacology of pain transmission. In: Wall PD, Melzack R, editors. The textbook of pain. London: Churchill Livingstone, 1989: 118-205
60. Max MB. Antidepressants as analgesics. In: Fields HL, Liebeskind JC, editors. Progress in pain research and management. Seattle: IASP Press, 1994: 229-46
61. Sindrup SH, Gram LF, Brosen K, et al. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990; 42: 135-44
62. Sindrup SH, Bjerre U, Dejgaard A, et al. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992; 52: 547-52
63. Kalso E, Tasmuth T, Neuvonen PJ. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain 1995; 64: 293-302
64. McQuay HJ, Carroll D, Glynn CJ. Dose-response for analgesic effect of amitriptyline in chronic pain. Anaesthesia 1993; 48: 281-5
65. Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill, 1996: 431-59
66. Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316: 363-9
67. Barbour CM, Tovell RM. Experiences with procaine administered intravenously. Ann Intern Med 1948; 10: 514-23
68. Boas RA, Covino BG, Shahnarian A. Analgesic responses to i.v. lidocaine. Br J Anaesth 1982; 54: 501-5
69. Edwards WT, Habib F, Burney RG, et al. Intravenous lidocaine in the management of various chronic pain states. Reg Anesth 1985; 10: 1-6
70. Kastrup J, Petersen P, Dejgard AEA. Intravenous lidocaine infusion - a new treatment of chronic painful neuropathy. Pain 1987; 28: 69-75
71. Ferrante FM, Paggioli J, Cherukuri S, et al. The analgesic response to intravenous lidocaine in the treatment of neuropathic pain. Anesth Analg 1996; 82: 91-7
72. Chabal C, Russell LC, Burchiel KJ. The effect of intravenous lidocaine, tocainide and mexiletine on spontaneously active fibers originating in rat sciatic neuromas. Pain 1989; 38: 333-8
73. Devor M, Wall P, Catalan N. Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction. Pain 1992; 48: 261-8
74. Woolf CJ, Wiesenfeld-Hallin Z. The systemic administration of local anaesthetics produces a selective depression of C-afferent fibre evoked activity in the spinal cord. Pain 1985; 23: 361-74
75. Arnér S, Lindblom U, Meyerson BA, et al. Prolonged relief of neuralgia after regional anesthetic blocks: a call for further experimental and systematic clinical studies. Pain 1990; 43: 287-97
76. Brose WG, Cousins MJ. Subcutaneous lidocaine for treatment of neuropathic cancer pain. Pain 1991; 45: 145-8
77. Devulder JE, Ghys L, Dhondt W, et al. Neuropathic pain in a cancer patient responding to subcutaneously administered lignocaine. Clin J Pain 1993; 9: 220-3
78. Marchettini P, Lacerenza M, Marangoni C, et al. Lidocaine test in neuralgia. Pain 1992; 48: 377-82
79. Dejgard A, Petersen P, Kastrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1988; I: 9-11
80. Stacke H, Meyer UE, Schumacher HE, et al. Mexiletine in the treatment of diabetic neuropathy. Diabetes Care 1992; 15: 1550-5
81. Chabal C, Jacobson L, Mariano A, et al. The use of oral mexiletine for the treatment of pain after peripheral nerve injury. Anesthesiology 1992; 76: 513-7
82. Impact Research Group. International Mexiletine and Placebo Antrarrhythmic Coronary Trial: I. Report on arrhythmia and other findings. J Am Coll Cardiol 1984; 4: 1148-63
83. Lindström P, Lindblom U. The analgesic effect of tocainide in trigeminal neuralgia. Pain 1987; 28: 45-50
84. McQuay H, Carroll D, Jadad AR, et al. Anticonvulsant drugs for management of pain: a systematic review. BMJ 1995; 311: 1047-52
85. Blom S. Trigeminal neuralgia: its treatment with a new anticonvulsant drug (G-32883). Lancet 1962 Apr; I: 839-40
86. McNamara JO. Drugs effective in the therapy of the epilepsies. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill, 1996: 461-86
87. Berde CH. New and old anticonvulsants for the management of pain. IASP Newsletter 1997 Jan/Feb: 3-5
88. Blom S. Tic douloureux treated with new anticonvulsant. Arch Neurol 1963; 9: 285-90
89. Patsalos PN. Phenobarbitone to gabapentin: a guide to 82 years of anti-epileptic drug pharmacokinetic interactions. Seizure 1994; 3: 163-70
90. Boivie J. Antiepileptic drugs for the treatment of neuropathic pain. In: Campbell JN, editor. Pain 1996 - an updated review. Seattle: IASP Press, 1996: 21-2
91. Benson RF, Parris WCV. Efficacy of gabapentin for neuropathic pain [abstract]. 8th World Congress on Pain. Seattle: IASP Press, 1996: 73
92. Rosner H, Rubin L, Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain 1996; 12: 56-8
93. Eisenberg E, Alon N. Lamotrigine in the treatment of painful diabetic neuropathy [abstract]. 8th World Congress on Pain. Seattle: IASP Press, 1996: 372
94. Wadelius M, Karlsson T, Wadelius C, et al. Lamotrigine and toxic epidermal necrolysis. Lancet 1996; 348: 1041
95. Kristensen J, Gordh T. Modulation of NMDA receptor function for pain treatment. In: Biebuyck JF, Lynch III C, Maze M, et al., editors. Anesthesia: biological foundations. Philadelphia: Lippencott-Raven. In press
96. Dickenson AH. A cure for wind-up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol Sci 1990; 11: 307-9
97. Woolf CJ, Thompson SWN. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation: implications for the treatment of post-injury pain hypersensitivity states. Pain 1991; 44: 293-9
98. Yaksh TL. Epidural ketamine: a useful, mechanistically novel adjuvant for epidural morphine? Reg Anesth 1996; 21: 508-13
99. Eide PK, Stubhaug A, Oye I, et al. Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia. Pain 1995; 61: 221-8
100. Mathisen LC, Skjelbred P, Skoglund LA, et al. Effects of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain. Pain 1995; 61: 215-20
101. Stannard CF, Porter GE. Ketamine hydrochloride in the treatment of phantom limb pain. Pain 1993; 54: 227-30
102. Stubhaug A, Breivik H. Longterm treatment of chronic neuropathic pain with the NMDA (N-methyl-D-aspartate) receptor antagonist ketamine. Acta Anaesthesiol Scand 1997; 41: 329-31
103. McQuay HJ, Carroll D, Jadad AR, et al. Dextromethorphan for the treatment of neuropathic pain: a double-blind randomised controlled crossover trial with integral n-of-1 design. Pain 1994; 59: 127-33
104. Nelson KA, Park KM, Robinovitz E, et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997; 48: 1212-8
105. Meller ST. Ketamine, relief from chronic pain through actions at the NMDA receptor? Pain 1996; 68: 435-6
106. Kristensen JD, Svensson BA, Gordh Jr T. The NMDA antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans. Pain 1992; 51: 249-53
107. Eisenach JC, De Kock M, Klimscha W. Alfa2-adrenergic agonists for regional anesthesia. Anesthesiology 1996; 85: 655-74
108. Xu Z, Li P, Tong C, et al. Location and characteristics of nitric oxide synthase in sheep spinal cord and its interaction with alpha2-adrenergic and cholinergic antinociception. Anesthesiology 1996; 84: 890-9
109. Tamsen A, Gordh T. Epidural clonidine produces analgesia. Lancet 1984; II: 231-2
110. Eisenach JC, DuPen S, Dubois M, et al. Epidural clonidine analgesia for intractable cancer pain: the Epidural Clonidine Study Group. Pain 1995; 61: 391-9
111. Rauck RL, Eisenach JC, Jackson K, et al. Epidural clonidine treatment for refractory reflex sympathetic dystrophy. Anesthesiology 1993; 79: 1163-9
112. Byas-Smith MG, Max MB, Muir J, et al. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage 'enriched enrollment' design. Pain 1995; 60: 267-74
113. Hanks GW, Justins DM. Cancer pain management. Lancet 1992; 339: 1031-5
114. Samuelsson H, Hedner T. Pain characterization in cancer patients and the analgesic response to epidural morphine. Pain 1991; 46: 3-8
115. Hanks GW, Forbes K. Opioid responsiveness. Acta Anaesthesiol Scand 1997; 41: 154-8
116. Hegarty A, Portenoy RK. Pharmacotherapy of neuropathic pain. Semin Neurol 1994; 14: 213-24
117. Rowbotham MC, Reisner Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991; 41: 1024-8
118. Choca JI, Proudfit HK, Green RD. Identification of A1 and A2 adenosine receptors in the rat spinal cord. J Pharmacol Exp Ther 1987; 242: 905-10
119. Fastbom J, Pazos A, Probst A, et al. Adenosine A1 receptors in the human brain: a quantitative autoradiographic study. Neuroscience 1987; 22: 827-39
120. Van Calker D, Müller M, Hamprecht B. Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J Neurochem 1979; 33: 999-1005
121. Karlsten R, Post C, Hide I, et al. The antinociceptive effect of intrathecally administered adenosine analogs in mice correlates with the affinity for the A1-adenosine receptor. Neurosci Lett 1991; 121: 267-70
122. Yamamoto T, Yaksh TL. Spinal pharmacology of thermal hyperesthesia induced by incomplete ligation of sciatic nerve: I. Opioid and nonopioid receptors. Anesthesiology 1991; 75: 817-26
123. Sosnowski M, Yaksh TL. Role of spinal adenosine receptors in modulating the hyperesthesia produced by spinal glycine receptor antagonism. Anesth Analg 1989; 69: 587-92
124. Lee Y-W, Yaksh TL. Pharmacology of the spinal adenosine receptor which mediates the antiallodynic action of intrathecal adenosine agonists. J Pharmacol Exp Ther 1996; 277: 1642-8
125. Reeve AJ, Dickenson AH. The roles of spinal adenosine receptors in the control of acute and more persistent nociceptive responses of dorsal horn neurons in the anaesthetized rat. Br J Pharmacol 1995; 116: 2221-8
126. Belfrage M, Sollevi A, Segerdahl M, et al. Systemic adenosine infusion alleviates spontaneous and stimulus evoked pain in patients with peripheral neuropathic pain. Anesth Analg 1995; 81: 713-7
127. Sollevi A, Belfrage M, Lundeberg T, et al. Systemic adenosine infusion: a new treatment modality to alleviate neuropathic pain. Pain 1995; 61: 155-8
128. Karlsten R, Gordh T. An A1-selective adenosine agonist abolishes allodynia elicited by vibration and touch after intrathecal injection. Anesth Analg 1995; 80: 844-7
129. Guieu R, Peragut JC, Roussel P, et al. Adenosine and neuropathic pain. Pain 1996; 68: 271-4
130. Meller ST, Gebhart GF. Nitric oxide (NO) and nociceptive processing in the spinal cord. Pain 1993; 52: 127-36
131. Siegan JB, Hama AT, Sagen J. Alteration in the rat spinal cord c-GMP by peripheral nerve injury and adrenal medullary transplantation. Neurosci Lett 1996; 215: 49-52
132. Meyerson BA. Mechanisms of spinal cord stimulation as pain treatment. In: Campbell JN, editor. Pain 1996 - an updated review. Seattle: IASP Press, 1996: 207-15
133. Nitescu P, Sjöberg M, Appelgren L, et al. Complications of intrathecal opioids and bupivacaine in the treatment of 'refractory' cancer pain. Clin J Pain 1995; 11: 45-62